QUantum Genomics Incremental Dosing in Heart Failure - QUID-HF (QUID-HF)
2018년 10월 11일 업데이트: Quantum Genomics SA
A Randomized, Double-blind, Multi-centre Study to Assess Safety and Efficacy of Incremental Doses of QGC001 in Patients With NYHA Class II/III Chronic Heart Failure (HF) With Left Ventricular Systolic Dysfunction Versus Placebo.
Heart Failure (HF) a common clinical condition characterized by either by a heart that does not pump sufficiently or becomes stiff. A variety of mechanisms contribute to progressive cardiac remodeling and dysfunction.
A new therapeutic approaches by preventing activation of the brain neuromodulatory pathway, may lead to improve HF.
QCG001 is a prodrug of EC33, a aminopeptidase A (APA) inhibitor. QCG001 has been shown to be an antihypertensive agent in animal models.
This study investigates the safety and efficacy of QGC001 in HF patients.
연구 개요
상세 설명
Despite advances in care, prognosis remains poor once overt Heart Failure (HF) has developed. HF is a common clinical condition characterized by either by a heart that does not pump sufficiently or becomes stiff and it is associates with higher incidences of patient illness and death in both case. A variety of mechanisms contribute to progressive cardiac remodeling and dysfunction.
A new therapeutic approaches by preventing activation of the brain neuromodulatory pathway, may lead to improve HF.
QCG001 is a prodrug of EC33, a specific and selective of the aminopeptidase A (APA) inhibitor. QCG001 has been shown to be an antihypertensive agent in animal models.
This study investigates the safety and efficacy of QGC001 up-titrated form 50mg twice daily to a maximum of 500 mg twice daily, on patients with worsening chronic HF during 28 days and 7 days after discontinuation (day 35).
6 European countries are involved in this study (France, Netherlands, Germany, Norway, Poland and United Kingdom) including 20 investigational hospitals. Patients would be followed during 35 days and inclusion period lasts until December 2017.
연구 유형
중재적
등록 (실제)
23
단계
- 2 단계
연락처 및 위치
이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.
연구 장소
-
-
-
Groningen, 네덜란드, 9713GZ
- University Medical Center Groningen
-
Maastricht, 네덜란드, PO 5800
- Maastricht University Medical Centre
-
-
-
-
-
Stavanger, 노르웨이, 4011
- Stavanger University Hospital
-
-
-
-
-
Berlin, 독일
- Charity Universitatsmedizin Berlin
-
Hannover, 독일, D-30625
- Medizinische Hochschule Hannover
-
Homburg, 독일, 66421
- Klinik für Innere Medizin III
-
-
-
-
-
Dundee, 영국, DD1 9SY
- Ninewells Hospital
-
-
England
-
Birmingham, England, 영국, B18 7QH
- University of Birmingham Institute of Cardiovascular Sciences City Hospital,
-
-
-
-
-
Frýdek-Místek, 체코, 73801
- Hospital of Fridek-Mistek P.O.
-
Praha, 체코, 12808
- General University Hospital
-
-
-
-
-
Wroclaw, 폴란드, 50981
- Clinical Military Hospital
-
Łódź, 폴란드, 94048
- NZOZ All-Med Centrum Medyczne
-
-
-
-
-
Bron, 프랑스, 69677
- Hopital Louis Pradel
-
Montpellier, 프랑스, 34295
- Hopital Arnaud de Villeneuve
-
Nancy, 프랑스, 54500
- CHRU NANCY
-
Nantes, 프랑스, 44093
- Hôpital Laennec
-
Paris, 프랑스, 75013
- Hôpital Pitie Salpétrière
-
Paris, 프랑스, 75015
- Georges Pompidou European Hospital
-
Rouen, 프랑스, 76031
- Hôpital Charles Nicolle
-
Strasbourg, 프랑스, 67000
- Hopitaux Universitaires de Strasbourg
-
Toulouse, 프랑스, 31000
- Clinique Pasteur
-
-
-
-
-
Budapest, 헝가리, 1134
- Magyar Honvedseg Egeszsegugyi Kozpont
-
Budapest, 헝가리, 1122
- Heart and Vascular Center of Semmelweis University
-
-
참여기준
연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.
자격 기준
공부할 수 있는 나이
18년 이상 (성인, 고령자)
건강한 자원 봉사자를 받아들입니다
아니
연구 대상 성별
모두
설명
Inclusion Criteria:
- A signed and dated informed consent form prior to any study procedure
- Adult male subjects and female subjects without childbearing potential.
- Clinical diagnosis of CHF with history of NYHA class II-III for at least 3 months before randomisation.
- Documented left ventricular ejection fraction (LVEF) < 40% measured by any modality within the previous 12 months in the subject's medical history.
- Subjects must also have at least one local measurement of BNP level ≥ 300 pg/mL or NT-proBNP level ≥ 1200 pg/mL (preferred assay, local laboratory) at the screening visit (maximum 7 days before randomisation).
- eGFR > 30 mL/min/1.73 m2 (MDRD) at screening.
- Serum potassium < 5.0 mmol/L at screening.
- Systolic blood pressure < 110 mmHg (average of 3 consecutive measurements) at screening.
- Prescribed to optimal pharmacologic therapy per "ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2016", or based on the updated current clinical practice, unless contra-indicated or not-tolerated, and on a stable dose for at least 30 days prior to enrolment (the dosage of the drugs cannot be increased or decreased respectively by more than double or half of initial dosage).
- Taking oral loop diuretics at doses < 250 mg furosemide daily (or equivalent).
Exclusion Criteria:
- BMI > 45 kg.m-2.
- Patients who require the use of HF IV therapy or oral furosemide > 250 mg (or equivalent) at any time during the 48 hours immediately before randomisation.
- Patients with unstable angina, myocardial infarction, PTCA, coronary artery bypass graft, cerebral vascular accident, or transient ischemic attack within previous 3 months (90 days) before enrolment.
- Patients whose primary cause of heart failure is mitral or aortic valve disease or congenital heart disease or hypertrophic obstructive cardiomyopathy or infiltrative cardiomyopathy (e.g. amyloidosis, sarcoidosis) or myocarditis.
- Patients with "new" permanent atrial fibrillation (AF), discovered within 3 months prior to randomization.
- Heart rate > 110 beats/min at screening.
- Patients scheduled for Pacemaker (including ICD, CRT), Angioplasty, CABG or LVAD within the next 3 months.
- Patients with severe documented chronic obstructive lung disease (COPD), defined as chronic need for oxygen therapy
- eGFR < 30 mL/min/1.73 m2 (MDRD) at screening.
- Decrease in eGFR greater than 20% within 3 weeks prior to the screening visit.
- Serum potassium > 5.0 mmol/L at screening.
- Systolic blood pressure < 110 mmHg or with signs or symptoms of hypotension.
- Symptomatic hypotension or orthostatic hypotension defined by a decrease of systolic blood pressure of more than 30 mm Hg in the standing vs. sitting position at screening and at the basal SBP of the D0 (before having taken the study medication).
- A marked baseline prolongation of QT/QTc interval (e.g. repeated demonstrated of a QTc interval > 450 ms) AND QRS < 100 ms. In case of QRS enlargement > 100 ms (i-e bundle branch block, pacemakers) QT does not accurately reflect repolarization and may not be calculated.
- A history of additional risk factors for Torsade de Pointes (TdP) (e.g. hypokalemia, family history of long QT Syndrome).
- The use of concomitant medications that prolong the QT/QTc interval.
- Insulin-requiring diabetic patients (including type 1 Diabetes).
- History of angioneurotic edema.
- Severe liver failure at screening defined by a value of ALAT and/or ASAT≥ 5 from the normal value.
- Patients involved in any interventional clinical study, patients enrolled in Registries and/or in non-interventional studies may participate.
- Patients who take an investigational or non-approved treatment.
- Women of childbearing potential.
- Patients with a prior cardiac transplant or patients currently on the list for cardiac transplantation.
- Patient with hypersensitivity to the active substance or to one of the other components of the trial preparation.
- Patients in whom an allergy requiring chronic treatment is known or exists.
- Patients with a history of previous illnesses of neurological or psychiatric nature that affect the Central Nervous System.
- Patients with a life expectancy of less than 12 months per physician judgment.
- Frail patient who, in the opinion of the investigator will not be able to follow the protocol.
공부 계획
이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 네 배로
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: QGC001
QGC001 from 50mg to 500mg capsule twice daily, for 28 days, oral use
|
|
|
위약 비교기: Placebo
Placebo, capsule twice daily, for 28 days, oral use
|
Lactose capsule manufactured to mimic QGC001 50 mg and 250 mg
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Relative decrease in NT-proBNP
기간: 28 days
|
Percentage of subjects with a relative decrease in NT-proBNP of more than 30% from Baseline to day 28.
|
28 days
|
|
Blood pressure change
기간: 28 days
|
Blood pressure changes at each visit (D7, D14, D21, D28), compared to the Baseline measure
|
28 days
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Blood biochemistry
기간: 35 days
|
blood biochemistry at D7, D14, D21, D28 and D35.
|
35 days
|
|
Urinary biochemistry
기간: 35 days
|
electrolytes, urinary osmolarity at D7, D14, D21, D28 and D35.
|
35 days
|
|
Change of NT-proBNP
기간: 35 days
|
Changes in central lab values of NT-proBNP at D7, D14, D21, D28 and D35.
|
35 days
|
|
Change of BNP
기간: 35 days
|
Changes in central lab values of BNP at D7, D14, D21, D28 and D35.
|
35 days
|
|
Change of selected biomarker levels
기간: 28 days
|
Changes in central lab values from baseline in selected biomarker levels (biomarkers involved in the pathophysiology of the disease, which will be decided later) at Day 7, Day 14, Day 21, Day 28
|
28 days
|
|
Quality of life Minnesota Living with Heart Failure Score
기간: 28 days
|
Quality of life Minnesota Living with Heart Failure Score and D0 and Day 28
|
28 days
|
공동 작업자 및 조사자
여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.
수사관
- 수석 연구원: Faiez Zannad, MD, Centre d'investigation clinique CHU-Nancy
연구 기록 날짜
이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.
연구 주요 날짜
연구 시작
2016년 6월 1일
기본 완료 (실제)
2018년 9월 12일
연구 완료 (실제)
2018년 9월 12일
연구 등록 날짜
최초 제출
2016년 5월 17일
QC 기준을 충족하는 최초 제출
2016년 5월 20일
처음 게시됨 (추정)
2016년 5월 23일
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
2018년 10월 16일
QC 기준을 충족하는 마지막 업데이트 제출
2018년 10월 11일
마지막으로 확인됨
2018년 10월 1일
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
- QUID-HF_v5.0_20171120
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
아니요
IPD 계획 설명
Individual participant date would be available only by the center via eCRF
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .